Full Press Release Details
Diagnostics to Hold a Business Update Conference Call on March 28, 2022
conference call and webcast at 4:30 PM EDT
YORK, March 7, 2022 (BUSINESS WIRE) - Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") a commercial-stage, cancer
prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the companies
will host a business update conference call on Monday, March 28, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman,
and Chief Executive Officer, will provide a business update including an overview of the Company's near-term milestones and growth
strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the companies' fourth quarter
2021 financial results.
access the conference call, U.S.-based listeners should dial 877-407-0789 and international listeners should dial 201-689-8562. All listeners
should provide the operator with the conference call name "Lucid Business Update Conference Call" to join. Individuals interested
in listening to the live conference call via the webcast may do so by visiting the investor relations section of the Company's
website at www.luciddx.com.
the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 from within
the U.S. or 412-317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 13727145.
The webcast will be available for replay on the investor relations section of the Company's website at www.luciddx.com.
Diagnostics Inc is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused
on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal
precancer and cancer. Lucid's EsoGuard Esophageal DNA Test, performed on samples collected in a brief, noninvasive office
procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable
of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk
GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as
a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and
is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building
a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing. For detailed information
press release includes forward-looking statements. Forward-looking statements are any statements that are not historical facts. Such
forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks
and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions;
the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory
submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical
studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once
cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition,
Lucid has been monitoring the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. Lucid expects the significance
of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other
things, the success of efforts to contain the pandemic and the impact of such efforts on Lucid's businesses. These factors are
difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties
that may affect Lucid's future operations, see Lucid's Registration Statement No. 333-259721 filed with the Securities and
Exchange Commission. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect
any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect
the likelihood that actual results will differ from those contained in the forward-looking statements.